ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) – Pipeline Review, H2 2016’, provides in depth analysis on ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) targeted pipeline therapeutics.

The report provides comprehensive information on the ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1)

The report reviews ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) targeted therapeutics and enlists all their major and minor projects

The report assesses ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Artery Therapeutics, Inc. 23

Galmed Pharmaceuticals Ltd 24

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) Overview 6

Therapeutics Development 7

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Products under Development by Stage of Development 7

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Products under Development by Therapy Area 8

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Products under Development by Indication 9

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Products under Development by Companies 12

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Products under Development by Universities/Institutes 14

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Companies Involved in Therapeutics Development 23

Artery Therapeutics, Inc. 23

Galmed Pharmaceuticals Ltd 24

Otsuka Holdings Co., Ltd. 25

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Drug Profiles 26

Aramchol - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Cogpep - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Dipep - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

IMMH-007 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

probucol - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Dormant Projects 36

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Discontinued Products 37

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Featured News & Press Releases 38

Sep 22, 2016: Galmed Pharmaceuticals and the University of California, San Diego Enter into an Investigator-Initiated Clinical Trial Agreement to Assess Aramchol Effects Juvenile Population 38

Jun 07, 2016: Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China 38

Jun 01, 2016: Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial 39

Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease 40

Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study 40

Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease 41

Aug 13, 2015: Galmed Pharmaceuticals Announces the Commencement of Patient Screening in the ARREST Study in the United States and Latin America 42

Mar 09, 2015: Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States 43

Jan 28, 2015: Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production 44

Dec 01, 2014: Galmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers 44

Nov 13, 2014: Galmed Pharmaceuticals Announces First Administration of Aramchol in its Phase IIa Trial for the Treatment of Cholesterol Gallstones 45

Sep 23, 2014: Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 45

Sep 02, 2014: Galmed Pharmaceuticals Completes Two Chronic Toxicology Studies and Reports No Significant Adverse Events 46

Jul 22, 2014: Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 47

Jul 08, 2014: Galmed Announces Publication of Aramchol Phase IIa Trial in the Clinical Gastroenterology and Hepatology Journal 48

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Artery Therapeutics, Inc., H2 2016 23

Pipeline by Galmed Pharmaceuticals Ltd, H2 2016 24

Pipeline by Otsuka Holdings Co., Ltd., H2 2016 25

Dormant Projects, H2 2016 36

Discontinued Products, H2 2016 37

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Mechanism of Actions, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports